{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T13:56:24Z","timestamp":1778162184745,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,5]]},"DOI":"10.7759\/cureus.14297","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T10:33:06Z","timestamp":1617618786000},"source":"Crossref","is-referenced-by-count":7,"title":["Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 Inhibitor Use and Recent Sleeve Gastrectomy"],"prefix":"10.7759","author":[{"given":"Alexander","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Holtrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moutamn","family":"Sadoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina55060268","article-title":"SGLT2 inhibitors: nephroprotective efficacy and side effects","volume":"55","author":"Garofalo C","year":"2019","unstructured":"Garofalo C, Borrelli S, Liberti ME, et al.. SGLT2 inhibitors: nephroprotective efficacy and side effects. Medicina (Kaunas). 2019, 55:268. 10.3390\/medicina55060268","journal-title":"Medicina (Kaunas)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-357. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg RM","year":"2016","unstructured":"Goldenberg RM, Berard LD, Cheng AYY, Gilbert JD, Verma S, Woo VC, Yale JF. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016, 38:2654-2664. 10.1016\/j.clinthera.2016.11.002","journal-title":"Clin Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2174\/1574886313666180226103408","article-title":"Risks associated with SGLT2 Inhibitors: an overview","volume":"13","author":"Singh M","year":"2018","unstructured":"Singh M, Kumar A. Risks associated with SGLT2 Inhibitors: an overview. Curr Drug Saf. 2018, 13:84-91. 10.2174\/1574886313666180226103408","journal-title":"Curr Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/BF00569937","article-title":"Euglycaemic diabetic ketoacidosis: does it exist?","volume":"30","author":"Jenkins D","year":"1993","unstructured":"Jenkins D, Close CF, Krentz AJ, Nattrass M, Wright AD. Euglycaemic diabetic ketoacidosis: does it exist?. Acta Diabetol. 1993, 30:251-253. 10.1007\/BF00569937","journal-title":"Acta Diabetol"},{"key":"ref6","article-title":"Euglycemic diabetic ketoacidosis","author":"Plewa MC","year":"2020","unstructured":"Plewa MC, Bryant M, King-Thiele R. Euglycemic diabetic ketoacidosis. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554570\/"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa W","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig. 2016, 7:135-138. 10.1111\/jdi.12401","journal-title":"J Diabetes Investig"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu H","year":"2017","unstructured":"Qiu H, Novikov A, Vallon V. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017, 33:2886. 10.1002\/dmrr.2886","journal-title":"Diabetes Metab Res Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner C","year":"2015","unstructured":"Bonner C, Kerr-Conte J, Gmyr V, et al.. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015, 21:512-517. 10.1038\/nm.3828","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2015.05.011","article-title":"SGLT-2 inhibition and glucagon: cause for alarm?","volume":"26","author":"Kibbey RG","year":"2015","unstructured":"Kibbey RG. SGLT-2 inhibition and glucagon: cause for alarm?. Trends Endocrinol Metab. 2015, 26: 337-338. 10.1016\/j.tem.2015.05.011","journal-title":"Trends Endocrinol Metab"},{"key":"ref11","article-title":"Section 22.5: Acetyl coenzyme a carboxylase plays a key role in controlling fatty acid metabolism","author":"Berg JM","year":"2002","unstructured":"Berg JM, Tymoczko JL, Stryer L. Section 22.5: Acetyl coenzyme a carboxylase plays a key role in controlling fatty acid metabolism. Biochemistry. 5th edition. W H Freeman, New York, NY; 2002. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK22381\/"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008632","article-title":"Effectiveness of bariatric surgical procedures: a systematic review and network meta-analysis of randomized controlled trials","volume":"96","author":"Kang JH","year":"2017","unstructured":"Kang JH, Le QA. Effectiveness of bariatric surgical procedures: a systematic review and network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017, 96:8632. 10.1097\/MD.0000000000008632","journal-title":"Medicine (Baltimore)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2647","article-title":"Incidence and clinical features of diabetic ketoacidosis after bariatric and metabolic surgery","volume":"39","author":"Aminian A","year":"2016","unstructured":"Aminian A, Kashyap SR, Burguera B, et al.. Incidence and clinical features of diabetic ketoacidosis after bariatric and metabolic surgery. Diabetes Care. 2016, 39:50-53. 10.2337\/dc15-2647","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis","volume":"22","author":"Handelsman Y","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. Endocr Pract. 2016, 22:753-762. 10.4158\/EP161292.PS","journal-title":"Endocr Pract"},{"key":"ref15","unstructured":"FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. (2020). Accessed. March 19, 2021: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-...."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14251","article-title":"Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations","volume":"73","author":"Milder DA","year":"2018","unstructured":"Milder DA, Milder TY, Kam PCA. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations. Anaesthesia. 2018, 73:1008-1018. 10.1111\/anae.14251","journal-title":"Anaesthesia"},{"key":"ref17","article-title":"[Euglycemic diabetic ketoacidosis caused by a sodium-glucose co-transporter (SGLT) 2 inhibitor after coronary artery bypass grafting]","volume":"72","author":"Kameda Y","year":"2019","unstructured":"Kameda Y, Kato M, Inoue B, et al.. [Euglycemic diabetic ketoacidosis caused by a sodium-glucose co-transporter (SGLT) 2 inhibitor after coronary artery bypass grafting]. Kyobu Geka. 2019, 72:354-357.","journal-title":"Kyobu Geka"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2165\/00024677-200302020-00003","article-title":"Diabetic ketoacidosis: risk factors and management strategies","volume":"2","author":"Umpierrez GE","year":"2003","unstructured":"Umpierrez GE, Kitabchi AE. Diabetic ketoacidosis: risk factors and management strategies. Treat Endocrinol. 2003, 2:95-108. 10.2165\/00024677-200302020-00003","journal-title":"Treat Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20461","article-title":"Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery","volume":"21","author":"Mechanick JI","year":"2013","unstructured":"Mechanick JI, Youdim A, Jones DB, et al.. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013, 21:1-27. 10.1002\/oby.20461","journal-title":"Obesity (Silver Spring)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/54908-post-operative-euglycemic-diabetic-ketoacidosis-in-a-patient-with-sglt-2-inhibitor-use-and-recent-sleeve-gastrectomy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:21Z","timestamp":1707507081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/54908-post-operative-euglycemic-diabetic-ketoacidosis-in-a-patient-with-sglt-2-inhibitor-use-and-recent-sleeve-gastrectomy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.14297","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,5]]}}}